The at-home testing kits market serves a wide range of applications, with the dominating segment being diagnostics. These kits allow individuals to self-administer tests for various medical conditions, including pregnancy, glucose monitoring, and infectious diseases such as COVID-19. Additionally, wellness and genetic testing kits are gaining popularity, enabling users to assess their health and ancestry. The convenience and privacy of at-home testing contribute to their widespread use, making diagnostics the leading segment in the market, followed closely by wellness and genetic testing.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/indonesia-at-home-testing-kits-market
Data Bridge Market Research analyses that the Indonesia At-Home Testing Kits Market is growing with a CAGR of 4.6% in the forecast period of 2022 to 2029 and is expected to reach IDR 16, 81,367.36 million by 2029 from IDR 10,13,289.31 million in 2021. At-home testing tends to be more cost-effective than in-clinic tests due to reduced overhead costs associated with healthcare facilities, eliminating the need for appointments, travel, and administrative fees, making it a budget-friendly option for many individuals.
Key Findings of the Study
The aging population is expected to drive the market's growth rate
The aging population is increasingly turning to more accessible methods of health monitoring. As people age, they often face chronic health conditions and require regular check-ups. At-home testing kits provide a convenient and non-invasive way for seniors to monitor their health without frequent visits to medical facilities. This trend aligns with the desire for independence and autonomy among older individuals, allowing them to proactively manage their health and potentially detect issues earlier
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in IDR Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Test Type (Pregnancy Test Kits, Other At-Home Test Kits, Narcotic Test Kits, HIV Test Kits, and Fertility Test Kits), Type of User (High Class, Middle Class, and Lower Class ), Type of Buyer (Pregnancy Test Kits, Other At-Home Test Kits, Narcotic Test Kits, HIV Test Kits and Fertility Test Kits), Process Location (At-Home and At-Home Lab Tests (Digital Results), Age (Adult, Geriatric and Pediatric), Brands (Pregnancy Test, Other At-Home Test, Narcotic Test, HIV Test and Fertility Test), Distribution Channel (Institutional Buyer and Retail/Branded Sales)
|
|
Countries Covered
|
Indonesia
|
|
Market Players Covered
|
Abbott (U.S.), PT. Danpac Pharma (Indonesia), Orient Gene (China), Siemens Healthcare GmbH (Germany), Medtronic (Ireland), BD (Becton, Dickinson and Company) (U.S.), B. Braun Melsungen AG (Germany), Quidel Corporation (U.S.), NIPRO (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), EGENS GROUP (South Korea), DKT INTERNATIONAL (U.S.), Clearblue (A subsidiary of SPD Swiss Precision Diagnostics GmbH) (Switzerland), ACON Laboratories, Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The Indonesia at-home testing kits market is segmented into test type, type of user, type of buyer, process location, age, brands, and distribution channel.
- On the basis of test type, the Indonesia at-home testing kits market is segmented into pregnancy test kits, other at-home test kits, narcotic test kits, HIV test kits, and fertility test kits
- On the basis of type of user, the Indonesia at-home testing kits market is segmented into high class, middle class and lower class
- On the basis of type of buyer, the Indonesia at-home testing kits market is segmented into pregnancy test kits, other at-home test kits, narcotic test kits, HIV test kits, and fertility test kits
- On the basis of process location, the Indonesia at-home testing kits market is segmented into at-home and at-home lab tests (digital results)
- On the basis of age, the Indonesia at-home testing kits market is segmented into adult, geriatric, and pediatric
- On the basis of brands, the Indonesia at-home testing kits market is segmented into pregnancy test, other at-home test, narcotic test, HIV test and fertility test
- On the basis of distribution channel, the Indonesia at-home testing kits market is segmented into institutional buyer and retail/branded sales
Major Players
Data Bridge Market Research recognizes the following companies as Indonesia at-home testing kits market players in Indonesia at-home testing kits market are Abbott (U.S.), PT. Danpac Pharma (Indonesia), Orient Gene (China), Siemens Healthcare GmbH (Germany), Medtronic (Ireland), BD (Becton, Dickinson and Company) (U.S.), B. Braun Melsungen AG (Germany), Quidel Corporation (U.S.).
Market Developments
- In November 2020, Quidel Corporation achieved a significant milestone by creating a rapid diagnostic test for COVID-19. This development led to the company receiving Emergency Use Authorization (EUA) from the FDA to launch and market the Sofia 2 SARS Antigen FIA, a point-of-care test for COVID-19. The EUA facilitated the test's deployment in the ongoing pandemic, contributing to increased sales and revenue for the company while playing a crucial role in combating the virus.
- In June 2022, Abbott Laboratories announced its plans to develop a continuous glucose and ketone monitoring device. This innovative device aims to empower individuals to easily and accurately track their glucose and ketone levels. Such a device can be particularly beneficial for people managing diabetes and those following ketogenic diets, offering real-time data to support better health management and lifestyle choices while enhancing Abbott Laboratories' position as a leader in healthcare technology.
- In September 2022, Morgan Health demonstrated its commitment to expanding access to at-home healthcare solutions by investing in LetsGetChecked. This strategic investment aims to facilitate broader availability of at-home medical testing and telehealth services, offering individuals convenient and accessible options for monitoring their health and wellness. The partnership with LetsGetChecked reflects a growing trend toward patient-centric healthcare delivery and the recognition of the value of remote health monitoring and diagnostics.
For more detailed information about Indonesia at-home testing kits market report, click here – https://www.databridgemarketresearch.com/de/reports/indonesia-at-home-testing-kits-market
